For example, glucagon-like peptide 1 agonists are licensed for the treatment of type 2 diabetes mellitus; however, genetic association data for type 2 diabetes mellitus risk specifically relate to the risk of developing the disease [66]. This evidence concerns the gene GCG and diabetes mellitus.